#### Edgar Filing: SANGAMO BIOSCIENCES INC - Form 4

SANGAMO Form 4 October 17,	D BIOSCIENCES 2014	INC									
FORM	ЛЛ								OMB AF	PROVAL	
	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287	
Check the	lis box								Expires:	January 31, 2005	
if no long subject to Section 1 Form 4 c	to <b>SIAIEN</b> 16.	STATEMENT OF CHANGES IN BENEFICIAL OW SECURITIES						ERSHIP OF	Estimated average burden hours per response (		
Form 5 obligatio may con <i>See</i> Insta 1(b).	ons Section 17(	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)										
LANPHIER EDWARD O II Symbol				т				5. Relationship of Reporting Person(s) to Issuer			
			SANGAMO BIOSCIENCES INC [SGMO]					(Check all applicable)			
(Last)	(First) (I	Middle)	3. Date of Earliest Transaction			_X_ Director 10% Owner _X_ Officer (give title Other (specify					
INC.,, POI	GAMO BIOSCIEN NT RICHMOND I CANAL BLVD		(Month/I 10/15/2	Day/Year) 2014				below)	below)	( ( p +	
			onth/Day/Year) A				6. Individual or Joint/Group Filing(Check Applicable Line)				
RICHMON	ND, CA 94804							_X_ Form filed by Or Form filed by Mo Person			
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Secu	rities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	ecurity (Month/Day/Year) Execution Date, if		3. 4. Securities Acquired (A) Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	OwnershipIncForm:BeDirect (D)Ov	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock	10/15/2014			М	25,000	А	\$ 4.11	320,000 <u>(3)</u>	D		
Common Stock	10/15/2014			S <u>(1)</u>	25,000	D	\$ 10.4946 (2)	5 295,000 <u>(3)</u>	D		
Common Stock								1,516,054	Ι	By Trust $(4)$	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 4.11	10/15/2014		М	25,000	(5)	12/11/2015	Common Stock	25,000

### **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships				
	Director	10% Owner	Officer	Other	
LANPHIER EDWARD O II C/O SANGAMO BIOSCIENCES INC., POINT RICHMOND TECH CNTR, 501 CANAL BLVD RICHMOND, CA 94804	Х		President & CEO		
Signatures					
/s/ Florence Tam, 10/17/2014					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 20, 2014.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.485 to \$10.56, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo

(2) BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

(3)

attorney-in-fact

\*\*Signature of Reporting Person

#### Edgar Filing: SANGAMO BIOSCIENCES INC - Form 4

Includes 100,000 shares, 120,000 shares, and 75,000 shares subject to restricted stock units granted on December 8, 2011, December 6, 2012, and December 12, 2013, respectively, that will be issued as such units vest in accordance with their terms.

- (4) These shares are held in the Edward O. Lanphier II and Cameron M. Lanphier Trust U/T/A August 30, 2002, Edward O. Lanphier II and Cameron M. Lanphier, Trustees.
- (5) All shares underlying these options are vested and exercisable immediately and such option will expire on December 11, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.